CNR1 gene and risk of the metabolic syndrome in patients with schizophrenia

Journal of Clinical Psychopharmacology

Volumn 33, Issue 2, 2013, Pages 186-192

  Yu, Weiping ^a   De Hert, Marc ^a   Moons, Tim ^b   Claes, Stephan J ^b   Correll, Christoph U ^c   Van Winkel, Ruud ^a,d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

endocannabinoid receptor type 1 gene; metabolic syndrome; schizophrenia

Indexed keywords

CLOZAPINE; ENDOCANNABINOID; ENDOCANNABINOID RECEPTOR 1; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DOPAMINERGIC TRANSMISSION; FEMALE; GENE FREQUENCY; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SEX RATIO; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; WAIST CIRCUMFERENCE;

EID: 84874939539     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318283925e     Document Type: Article

References (82)

1. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry. 1997;171:502-508. (Pubitemid 27527317)
2. Kelly DL, McMahon RP, Liu F, et al. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry. 2010;3:304-311.
3. Osborn DP, Wright CA, Levy G, et al. Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis. BMC Psychiatry [serial online]. September 2008;84:1-14. Available at: http://www.biomedcentral.com/ 1471-244X/8/84. Accessed February 20, 2012.
4. De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;1:52-77.
5. Khatana SA, Kane J, Taveira TH, et al. Monitoring and prevalence rates of metabolic syndrome in military veterans with serious mental illness. PLoS One [serial online]. May 2011;4:e19298. Available at: http://www.plosone.org/ article/info%3Adoi%2F10.1371%2Fjournal.pone.0019298. Accessed February 20, 2012.
6. Mitchell AJ, Vancampfort D, Sweers K, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disordersVa systematic review and meta-analysis. Schizophr Bull. 2011. [Epub ahead of print].
7. De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;2:114-126.
8. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;16:1765-1773.
9. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients. Neuropsychopharmacology. 2010;9:1997-2004.
10. Tarricone I, Ferrari Gozzi B, Serretti A, et al. Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychol Med. 2010;2:187-200.
11. De Hert M, Dobbelaere M, Sheridan EM, et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;3:144-158.
12. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;2-3:225-233.
13. De Hert M, Schreurs V, Sweers K, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res. 2008;1-3:295-303.
14. Holt RI, Peveler RC. Obesity, serious mental illness and antipsychotic drugs. Diabetes Obes Metab. 2009;7:665-679.
15. Elman I, Borsook D, Lukas SE. Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology. 2006;10:2091-2120. (Pubitemid 44413188)
16. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatmentVpharmacological mechanisms. Pharmacol Ther. 2009;1:169-179.
17. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011;2:97-107.
18. Coccurello R, Moles A. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther. 2010;3:210-251.
19. Balt SL, Galloway GP, Baggott MJ, et al. Mechanisms and genetics of antipsychotic-associated weight gain. Clin Pharmacol Ther. 2011; 90:179-183.
20. Lett TA, Wallace TJ, Chowdhury NI, et al. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry. 2012;3:242-266.
21. Wang YC, Bai YM, Chen JY, et al. Genetic association between TNF-alpha-308 G9A polymorphism and longitudinal weight change during clozapine treatment. Hum Psychopharmacol. 2010;4:303-309.
22. Ujike H, Nomura A, Morita Y, et al. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J Clin Psychiatry. 2008;9:1416-1422.
23. Jassim G, Ferno J, Theisen FM, et al. Association study of energy homeostasis genes and antipsychotic-induced weight gain in patients with schizophrenia. Pharmacopsychiatry. 2011;1:15-20.
24. Mulder H, Cohen D, Scheffer H, et al. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J Clin Psychopharmacol. 2009;1:16-20.
25. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet. 2002;9323:2086-2087. (Pubitemid 34680975)
26. Vehof J, Risselada AJ, Al Hadithy AF, et al. Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication. Psychopharmacology (Berl). 2011;2:257-265.
27. Risselada AJ, Vehof J, Bruggeman R, et al. Association between the 1291-C/G polymorphism in the adrenergic alpha-2a receptor and the metabolic syndrome. J Clin Psychopharmacol. 2010;6:667-671.
28. Ferno J, Skrede S, Vik-Mo AO, et al. Lipogenic effects of psychotropic drugs: focus on the SREBP system. Front Biosci. 2011;16:49-60.
29. Kristiana I, Sharpe LJ, Catts VS, et al. Antipsychotic drugs up-regulate lipogenic gene expression by disrupting intracellular trafficking of lipoprotein-derived cholesterol. Pharmacogenomics J. 2009;5:396-407.
30. Souza RP, De Luca V, Muscettola G, et al. Association of antipsychotic induced weight gain and body mass index with GNB3 gene: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2008;8:1848-1853.
31. Perez-Iglesias R, Mata I, Amado JA, et al. Effect of FTO, SH2B1, LEP, and LEPR polymorphisms on weight gain associated with antipsychotic treatment. J Clin Psychopharmacol. 2010;6:661-666.
32. Van Winkel R, Rutten BP, Peerbooms O, et al. MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr Res. 2010;1-3:193-198.
33. Moons T, Claes S, Martens GJ, et al. Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs. Schizophr Res. 2011;2-3:187-193.
34. Dinu IR, Popa S, Bicu M, et al. The implication of CNR1 gene's polymorphisms in the modulation of endocannabinoid system effects. Rom J Intern Med. 2009;1:9-18.
35. Ujike H, Takaki M, Nakata K, et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry. 2002;5:515-518. (Pubitemid 34712904)
36. Chavarria-Siles I, Contreras-Rojas J, Hare E, et al. Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2008;3:279-284. (Pubitemid 351536789)
37. Benzinou M, Chevre JC, Ward KJ, et al. Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations. Hum Mol Genet. 2008;13:1916-1921. (Pubitemid 351865840)
38. Feng Q, Jiang L, Berg RL, et al. A common CNR1 (cannabinoid receptor 1) haplotype attenuates the decrease in HDL cholesterol that typically accompanies weight gain. PLoS One [serial online]. January 2011;12:e15779. Available at: http://www.plosone.org/article/info:doi%2F10.1371%2Fjournal.pone.0015779. Accessed February 20, 2012.
39. Jaeger JP, Mattevi VS, Callegari-Jacques SM, et al. Cannabinoid type-1 receptor gene polymorphisms are associated with central obesity in a Southern Brazilian population. Dis Markers. 2008;1:67-74.
40. D'Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/ schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci. 2009;7:413-431.
41. Fernandez-Espejo E, Viveros MP, Nunez L, et al. Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology (Berl). 2009;4:531-549.
42. Kyrou I, Valsamakis G, Tsigos C. The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome. Ann N Y Acad Sci. 2006;1083:270-305. (Pubitemid 44955478)
43. Carriba P, Ortiz O, Patkar K, et al. Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology. 2007;11:2249-2259. (Pubitemid 47587686)
44. Wong DF, Kuwabara H, Horti AG, et al. Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage. 2010;4:1505-1513.
45. Patel PN, Pathak R. Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity. Am J Health Syst Pharm. 2007;5:481-489. (Pubitemid 46339261)
46. Pang Z, Wu NN, Zhao W, et al. The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice. Obesity (Silver Spring). 2011;10:1923-1934.
47. Aberle J, Flitsch J, Beck NA, et al. Genetic variation may influence obesity only under conditions of diet: analysis of three candidate genes. Mol Genet Metab. 2008;3:188-191.
48. Baye TM, Zhang Y, Smith E, et al. Genetic variation in cannabinoid receptor 1 (CNR1) is associated with derangements in lipid homeostasis, independent of body mass index. Pharmacogenomics. 2008;11:1647-1656.
49. Russo P, Strazzullo P, Cappuccio FP, et al. Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. J Clin Endocrinol Metab. 2007;6:2382-2386. (Pubitemid 46997151)
50. de Luis DA, Gonzalez Sagrado M, Aller R, et al. Influence of G1359A polymorphism of the cannabinoid receptor gene on anthropometric parameters and insulin resistance in women with obesity. Metabolism. 2011;2:272-276.
51. de Luis DA, Gonzalez Sagrado M, Aller R, et al. Relation of G1359A polymorphism of the cannabinoid receptor (CB1) gene with metabolic syndrome by ATP III classification. Diabetes Metab Res Rev. 2011;5:506-511.
52. He C, Kraft P, Chasman DI, et al. A large-scale candidate gene association study of age at menarche and age at natural menopause. Hum Genet. 2010;5:515-527.
53. Muller TD, Reichwald K, Wermter AK, et al. No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents. Mol Genet Metab. 2007;4:429-434. (Pubitemid 46484433)
54. Tiwari AK, Zai CC, Likhodi O, et al. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacology. 2010;6:1315-1324.
55. Monteleone P, Milano W, Petrella C, et al. Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain. J Clin Psychopharmacol. 2010;4:441-445.
56. Park YM, Choi JE, Kang SG, et al. Cannabinoid type 1 receptor gene polymorphisms are not associated with olanzapine-induced weight gain. Hum Psychopharmacol. 2011;4-5:332-337.
57. Smeets R, Dingemans P. Composite International Diagnostic Interview (CIDI) version 1.1. Amsterdam/Geneva: World Health Organization; 1993.
58. De Hert MA, van Winkel R, Van Eyck D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006;1:87-93.
59. van Winkel R, van Os J, Celic I, et al. Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program. J Clin Psychiatry. 2008;8:1319-1327.
60. De Hert M, Wampers M, Jendricko T, et al. Effects of cannabis use on age at onset in schizophrenia and bipolar disorder. Schizophr Res. 2011;1-3:270-276.
61. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;17:2735-2752. (Pubitemid 41532612)
62. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008;31:S55YS60.
63. van Winkel R. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry. 2011;68:148-157.
64. Fardo DW, Becker KD, Bertram L, et al. Recovering unused information in genome-wide association studies: the benefit of analyzing SNPs out of Hardy-Weinberg equilibrium. Eur J Hum Genet. 2009;12:1676-1682.
65. Cleves MA. Hardy-Weinberg equilibrium tests and allele frequency estimation. STATA Technical Bulletin. 1999;8:34-37.
66. Decoster J, van Os J, Kenis G, et al. Age at onset of psychotic disorder: cannabis, BDNF Val66Met, and sex-specific models of gene-environment interaction. Am J Med Genet B Neuropsychiatr Genet. 2011;3:363-369.
67. Cordell HJ, Clayton DG. Genetic association studies. Lancet. 2005;9491:1121-1131. (Pubitemid 41338767)
68. Frost M, Nielsen TL, Wraae K, et al. Polymorphisms in the endocannabinoid receptor 1 in relation to fat mass distribution. Eur J Endocrinol. 2010;3:407-412.
69. Laczmanski L, Milewicz A, Dunajska K, et al. Endocannabinoid type 1 receptor gene (CNR1) polymorphisms (rs806381, rs10485170, rs6454674, rs2023239) and cardiovascular risk factors in postmenopausal women. Gynecol Endocrinol. 2011;12:1023-1027.
70. Milewicz A, Tworowska-Bardzinska U, Jedrzejuk D, et al. Are endocannabinoid type 1 receptor gene (CNR1) polymorphisms associated with obesity and metabolic syndrome in postmenopausal Polish women Int J Obes (Lond). 2011;3:373-377.
71. Hu WC, Feng P. G1359A polymorphism in the cannabinoid receptor-1 gene is associated with metabolic syndrome in the Chinese Han population. Arch Med Res. 2010;5:378-382.
72. Bermudez-Silva FJ, Cardinal P, Cota D. The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. J Psychopharmacol. 2012;26:1-11.
73. Di Marzo V, Piscitelli F, Mechoulam R. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handb Exp Pharmacol. 2011;203:75-104.
74. Osei-Hyiaman D, Liu J, Zhou L, et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest. 2008;9:3160-3169.
75. Bell-Anderson KS, Aouad L, Williams H, et al. Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice. Int J Obes (Lond). 2011;12:1539-1548.
76. Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia. 2008;8:1356-1367.
77. Sarzani R, Bordicchia M, Marcucci P, et al. Altered pattern of cannabinoid type 1 receptor expression in adipose tissue of dysmetabolic and overweight patients. Metabolism. 2009;3:361-367.
78. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005;5:1298-1305. (Pubitemid 40629049)
79. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;3:423-431. (Pubitemid 38063771)
80. Burdyga G, Varro A, Dimaline R, et al. Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics and role in influencing neurochemical phenotype. Am J PhysiolGastrointest Liver Physiol. 2010;1:63-69.
81. Cota D, Steiner MA, Marsicano G, et al. Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology. 2007;4:1574-1581. (Pubitemid 46457104)
82. Burdyga G, Varro A, Dimaline R, et al. Ghrelin receptors in rat and human nodose ganglia: putative role in regulating CB-1 and MCH receptor abundance. Am J Physiol Gastrointest Liver Physiol. 2006;6:1289-1297.